title: Prevention of cardiotoxicity among survivors of childhood cancer.
abstract: This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381 The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.
authors: Department of Pediatric Hematology/Oncology, Children's Hospital of Michigan, 3901 Beaubien Boulevard, Detroit, Michigan, 48201, USA.
authors: Kelley K
authors: KK
authors: Hutchins
authors: Department of Pediatrics, Children's Hospital of Michigan, 3901 Beaubien Boulevard, Detroit, Michigan, 48201, USA.
authors: Hani
authors: H
authors: Siddeek
authors: Department of Pediatrics, Wayne State University School of Medicine, 3901 Beaubien Boulevard, Suite 1K40, Detroit, Michigan, 48201, USA.
authors: Vivian I
authors: VI
authors: Franco
authors: Department of Pediatrics, Wayne State University School of Medicine, 3901 Beaubien Boulevard, Suite 1K40, Detroit, Michigan, 48201, USA.|Karmanos Cancer Institute, Children's Hospital of Michigan.
authors: Steven E
authors: SE
authors: Lipshultz
mesh_terms: D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000073116:Cancer Survivors; D002316:Cardiotonic Agents / Q000627:therapeutic use; D066126:Cardiotoxicity / Q000517:prevention & control*; D064730:Dexrazoxane / Q000627:therapeutic use*; D006801:Humans; D008955:Models, Cardiovascular
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D002316:Cardiotonic Agents; D064730:Dexrazoxane
keywords: cardiotoxicity; childhood cancer; dexrazoxane; survivor